Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 8 records in total 8
    records per page




    Broncho- alveolar inflammation MESHD in COVID-19 patients: a correlation with clinical outcome

    Authors: laura pandolfi; Fossali Tommaso; Frangipane Vanessa; Bozzini Sara; Morosini Monica; D’Amato Maura; Lettieri Sara; Urtis Mario; Di Toro Alessandro; Saracino Laura; Percivalle Elena; Tomaselli Stefano; Cavagna Lorenzo; Cova Emanuela; Mojoli Francesco; Bergomi Paola; Ottolina Davide; Lilleri Daniele; Corsico Angelo Guido; Arbustini Eloisa; Colombo Riccardo; Meloni Federica

    doi:10.21203/rs.3.rs-49968/v1 Date: 2020-07-28 Source: ResearchSquare

    Background Severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) rapidly reached pandemic proportions. We conducted a prospective study to assess deep lung inflammatory status in patients with moderate to severe COVID-19.Methods Diagnostic bronchoalveolar lavage (BAL) was performed in 33 adult TRANS patients with SARS-CoV-2 infection MESHD by real-time PCR on nasopharyngeal swab admitted to the Intensive care unit (ICU) (n = 28) and to the Intermediate Medicine Ward (IMW) (n = 5). We analyze the differential cell count, ultrastructure of cells and Interleukin(IL)6, 8 and 10 levels.Results ICU patients showed a marked increase in neutrophils (72%, 60–81), lower lymphocyte (8%, 4–12) and macrophages fractions (17%, 11–27) compared to IMW patients (3%, 2–17, 15%, 6–26 and 74%, 58–90, respectively) (p < 0.01). Ultrastructural study from ICU patients showed viral-like particles in cytopathic mononuclear cells however extensive cytopathic damage in all cell lineages. Immunostaining with anti-viral capsid and spike antibodies SERO specifically immunoreacted with BAL cells, mostly cytopathic ones. IL6 and IL8 were significantly higher in ICU patients than in IMW (IL6 p < 0.01, IL8 p < 0.0001), and also in patients who did not survive (IL6 p < 0.05, IL8 p = 0.05 vs. survivors). IL10 did not show a significant variation between groups. Dividing patients by treatment received, lower BAL concentrations of IL6 were found in patients treated with steroids as compared to those treated with tocilizumab (p < 0.1) or antivirals (p < 0.05). Conclusions Alveolitis MESHD, associated with COVID-19, is mainly sustained by innate effectors which showed features of extensive activation. The burden of pro-inflammatory cytokines IL6 and IL8 in the broncho- alveolar MESHD environment is associated with clinical outcome.

    Broncho- alveolar inflammation MESHD in COVID-19 patients: a correlation with clinical outcome

    Authors: Laura Pandolfi; Fossali Tommaso; Frangipane Vanessa; Bozzini Sara; Morosini Monica; D’Amato Maura; Lettieri Sara; Urtis Mario; Di Toro Alessandro; Saracino Laura; Percivalle Elena; Tomaselli Stefano; Cavagna Lorenzo; Cova Emanuela; Mojoli Francesco; Bergomi Paola; Ottolina Davide; Lilleri Daniele; Corsico Angelo Guido; Arbustini Eloisa; Colombo Riccardo; Meloni Federica

    doi:10.21203/rs.3.rs-49968/v2 Date: 2020-07-28 Source: ResearchSquare

    Background: Severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) rapidly reached pandemic proportions. Given that the main target of SARS-CoV-2 are lungs leading to severe pneumonia HP pneumonia MESHD with hyperactivation of the inflammatory cascade, we conducted a prospective study to assess alveolar MESHD inflammatory status in patients with moderate to severe COVID-19. Methods: Diagnostic bronchoalveolar lavage (BAL) was performed in 33 adult TRANS patients with SARS-CoV-2 infection MESHD by real-time PCR on nasopharyngeal swab admitted to the Intensive care unit (ICU) (n=28) and to the Intermediate Medicine Ward (IMW) (n=5). We analyze the differential cell count, ultrastructure of cells and Interleukin(IL)6, 8 and 10 levels.Results: ICU patients showed a marked increase in neutrophils (1.24 x 105 ml-1 , 0.85-2.07), lower lymphocyte (0.97 x 105 ml-1, 0.024-0.34) and macrophages fractions (0.43 x 105 ml-1, 0.34-1.62) compared to IMW patients (0.095 x 105 ml-1, 0.05-0.73; 0.47 x 105 ml-1, 0.28-1.01 and 2.14 x 105 ml-1, 1.17-3.01, respectively) (p<0.01). Ultrastructural study of ICU patients BAL showed viral-like particles in cytopathic mononuclear cells and an extensive cytopathic damage in all cell lineages. Immunostaining with anti-viral capsid and spike antibodies SERO specifically immunoreacted with BAL cells, mostly cytopathic ones. IL6 and IL8 were significantly higher in ICU patients than in IMW (IL6 p<0.01, IL8 p<0.0001), and also in patients who did not survive (IL6 p < 0.05, IL8 p = 0.05 vs. survivors). IL10 did not show a significant variation between groups. Dividing patients by treatment received, lower BAL concentrations of IL6 were found in patients treated with steroids as compared to those treated with tocilizumab (p<0.1) or antivirals (p<0.05). Conclusions: Alveolitis MESHD, associated with COVID-19, is mainly sustained by innate effectors which showed features of extensive activation. The burden of pro-inflammatory cytokines IL6 and IL8 in the broncho- alveolar MESHD environment is associated with clinical outcome.

    Broncho- alveolar inflammation MESHD in COVID-19 patients: a correlation with clinical outcome

    Authors: Laura Pandolfi; Tommaso Fossali; Vanessa Frangipane; Sara Bozzini; Monica Morosini; Maura D'Amato; Sara Lettieri; Mario Urtis; Alessandro Di Toro; Laura Saracino; Elena Percivalle; Stefano Tomaselli; Lorenzo Cavagna; Emanuela Cova; Francesco Mojoli; Paola Bergomi; davide ottolina; Daniele Lilleri; Angelo Guido Corsico; Eloisa Arbustini; Riccardo Colombo; Federica Meloni

    doi:10.1101/2020.07.17.20155978 Date: 2020-07-17 Source: medRxiv

    Severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) rapidly reached pandemic proportions. We conducted a prospective study to assess deep lung inflammatory status in patients with moderate to severe COVID-19. Diagnostic bronchoalveolar lavage (BAL) was performed in 33 adult TRANS patients with SARS-CoV-2 infection MESHD by real-time PCR on nasopharyngeal swab admitted to the Intensive care unit (ICU) (n=28) and to the Intermediate Medicine Ward (IMW) (n=5). We analyze the differential cell count, ultrastructure of cells and Interleukin(IL)6, 8 and 10 levels. ICU patients showed a marked increase in neutrophils (72%, 60-81), lower lymphocyte (8%, 4-12) and macrophages fractions (17%, 11-27) compared to IMW patients (3%, 2-17, 15%, 6-26 and 74%, 58-90, respectively) (p<0.01). Ultrastructural study from ICU patients showed viral-like particles in cytopathic mononuclear cells however extensive cytopathic damage in all cell lineages. Immunostaining with anti-viral capsid and spike antibodies SERO specifically immunoreacted with BAL cells, mostly cytopathic ones. IL6 and IL8 were significantly higher in ICU patients than in IMW (IL6 p<0.01, IL8 p<0.0001), and also in patients who did not survive (IL6 p < 0.05, IL8 p = 0.05 vs. survivors). IL10 did not show a significant variation between groups. Dividing patients by treatment received, lower BAL concentrations of IL6 were found in patients treated with steroids as compared to those treated with tocilizumab (p<0.1) or antivirals (p<0.05). Alveolitis MESHD, associated with COVID-19, is mainly sustained by innate effectors which showed features of extensive activation. The burden of pro-inflammatory cytokines IL6 and IL8 in the broncho- alveolar MESHD environment is associated with clinical outcome

    Menstrual blood SERO-derived mesenchymal stem cells provide new insights into the treatment of coronavirus disease MESHD 2019 (COVID-19)

    Authors: Xin Chen; Liang Yu; Lijun Chen; Xiaoqin Zheng; Lingling Tang; Kaijin Xu; Hongliu Cai; Yu Chen; Shufa Zheng; Juan Lu; Zhenyu Xu; Qiang Zhang; Hainv Gao; Yifei Li; Jingjing Qu; Yingan Jiang; Xiaowei Xu; Charlie Xiang; Lanjuan Li

    doi:10.21203/rs.3.rs-25947/v1 Date: 2020-04-29 Source: ResearchSquare

    Background: The coronavirus disease MESHD 2019 (COVID-19) causing a cluster of respiratory infections MESHD in Wuhan, China, is identified in December 2019. The main symptoms are defined as fever HP fever MESHD, cough HP cough MESHD, shortness of breath MESHD, with early symptom of sputum, acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD), and the final lung injury MESHD and pulmonary fibrosis HP pulmonary fibrosis MESHD. Currently, there is no effective method to cure it. Mesenchymal stem cell (MSC) therapy is an immediate need for treating COVID-19 especially severe patients at present.Methods: We describe the two confirmed case TRANS of COVID-19 severe patients in Hangzhou, China to explore the role of menstrual blood SERO-derived MSC in the treatment of SARS-CoV-2 infection MESHD. Furthermore, we mimic disease model of pulmonary fibrosis HP pulmonary fibrosis MESHD in mice to assess the role of MSC. Then, a co-culture system to investigate the underlying mechanism between MSC and pulmonary-associated cells by a series of Physiological, biochemical, bioinformatics analysis.Results: MSC transplantation increases the immune indicators (including lymphocytes) and decreases inflammatory indicators (such as IL-6, IL-10, TNF, and IFN). More importantly, the two patients alleviated symptom and discharged after 3 weeks’ treatment with MSC MESHD. Additionally, MSCs exhibit an anti-inflammatory role through suppressing some inflammatory factors (RANTES, GM-CSF, MIG-1g, MCP-5, Eotaxin), which is anastomotic to current clinical study using MSC to treat COVID-19. Conclusions: This is the first report using menstrual blood SERO-derived MSC in treating COVID-19 patients. From our clinical results, we hold one idea that MSCs reduced inflammatory effect to defend cytokine storm. The underlying mechanism is probably that MSCs inhibit epithelia cell apoptosis and reduce the secretion of inflammatory factors to prevent myofibroblasts activity. MSC provides an alternative method for treating COVID-19 particularly some patients with ARDS MESHD or subsequent pulmonary fibrosis HP pulmonary fibrosis MESHD.Trial registration: This clinical trial was submitted to and approved by the Ethics Committee of the First Affiliated Hospital, Collage of Medicine, Zhejiang University. MSC administration in patient with COVID-19 was conducted in a single center and open-label clinical trial (ChiCTR2000029606).

    Pulmonary function of patients with 2019 novel coronavirus induced pneumonia HP pneumonia MESHD: A Retrospective Cohort Study

    Authors: Dongqing Lv; Xi Chen; Linghong Mao; Jiao Sun; Guixian Wu; Zhi Lin; Ronghai Lin; Jiansong Yu; Xiaomai Wu; Yongpo Jiang

    doi:10.21203/rs.3.rs-24303/v1 Date: 2020-04-21 Source: ResearchSquare

    Background: Pulmonary fibrosis HP Pulmonary fibrosis MESHD is a common complication in patients with viral pneumonia MESHD pneumonia HP, which causes restricted ventilation disorders MESHD and affects the prognosis of patients. However, the pulmonary function of patients with 2019 novel coronavirus (COVID-19)-induced pneumonia HP pneumonia MESHD has not yet been reported.Methods: A retrospective analysis of 137 patients with COVID-19-induced pneumonia HP pneumonia MESHD who were discharged from the Enze Hospital, Taizhou Enze Medical Center (Group), from January 31, 2020, to March 11, 2020. Follow-up occurred two weeks after hospital discharge, whereupon patients received a pulmonary function test. Results: Of the 137 patients who received a pulmonary function test two weeks after discharge, 51.8% were male TRANS, and the mean age TRANS was 47 years. Only 19.7% of the patients were identified as having severe novel coronavirus pneumonia MESHD pneumonia HP. The pulmonary function test showed that for a small number of patients ((FEV1/FVC)/% <70%,) the mean ICV and FVC was 2.4±0.7 L, 3.2±0.8 L, respectively. In severe cases, 88.9% of patients had an IVC <80% of the predicted value and 55.6% of patients had an FVC <80% of the predicted value. The MEF25, MEF50, and MEF75 <70% values were 55.6%, 40.7%, and 25.9%, respectively. In the non-severe group, 79.1% of patients has an IVC <80% of the predicted value, and 16.4% of patients had an FVC <80% of the predicted value. The mean MEF25, MEF50, and MEF75 <70% values were 57.3%, 30%, and 13.6%, respectively.Conclusions: In this study, the results suggest that the pulmonary function of patients with 2019 novel coronavirus (COVID-19)-induced pneumonia HP pneumonia MESHD manifested as restrictive ventilation disorder MESHD and small airway obstruction. The incidence was increased among critically ill patients.Trial registration number: ChiCTR2000029866.

    Single-cell RNA Analysis on ACE2 Expression Provides Insight into SARS-CoV-2 Blood SERO Entry and Heart Injury

    Authors: Jieyu Guo; Xiangxiang Wei; Qinhan Li; Liliang Li; Zhaohua Yang; Yu Shi; Yue Qin; Xinyue Zhang; Xinhong Wang; Xiuling Zhi; Dan Meng

    doi:10.1101/2020.03.31.20047621 Date: 2020-04-04 Source: medRxiv

    COVID-19 is a global pandemic with high infectivity and pathogenicity, accounting for tens of thousands of deaths worldwide. Recent studies have found that the pathogen of COVID-19, SARS-CoV-2, shares the same cell receptor Angiotensin converting enzyme II (ACE2) with SARS-CoV MESHD. The pathological investigation of COVID-19 death showed that the lung had the characteristics of pulmonary fibrosis HP pulmonary fibrosis MESHD. However, how SARS-CoV-2 spreads from the lungs to other organs has not yet been determined. Here, we performed an unbiased evaluation of cell-type specific expression of ACE2 in healthy and fibrotic lungs, as well as in normal and failed adult TRANS human hearts, using published single-cell RNA-seq data. We found that ACE2 expression in fibrotic lungs mainly locates in arterial vascular cells, which might provide the route for bloodstream spreading of SARS-CoV-2. The failed human hearts have a higher percentage of ACE2-expressing cardiomyocytes, and SARS-CoV-2 might attack cardiomyocytes through the bloodstream in patients with heart failure MESHD. Moreover, ACE2 was highly expressed in cells infected by RSV or MERS-CoV MESHD and in mice treated by LPS. Our findings indicate that patients with pulmonary fibrosis HP pulmonary fibrosis MESHD, heart failure MESHD, and virus infection MESHD have a higher risk and are more susceptible to SARS-CoV-2 infection MESHD. SARS-CoV-2 might attack other organs by getting into the bloodstream. This work provides new insights into SARS-CoV-2 blood entry MESHD blood SERO entry and heart injury MESHD and might propose a therapeutic strategy to prevent patients from developing severe complications.

    The novel coronavirus (COVID-19) pneumonia HP pneumonia MESHD with negative detection of viral ribonucleic acid from nasopharyngeal swabs: A case report

    Authors: Peiyan Zhang; Zhao Cai; Weibo Wu; Ling Peng; Yinfeng Li; Chuming Chen; Li Chen; Jianming Li; Mengli Cao; Shiyan Feng; Xiao Jiang; Jing Yuan; Yingxia Liu; Liang Yang; Fuxiang Wang

    doi:10.21203/rs.3.rs-18659/v1 Date: 2020-03-20 Source: ResearchSquare

    BackgroundThe novel coronavirus disease MESHD 2019 (COVID-19) outbreak started in Wuhan, Hubei, China since Dec 2019 and cases of infection MESHD have been continuously reported in various countries. It is now clear that the COVID-19 coronavirus is transmissible from human to human. Nucleic acid detection is considered as the gold standard for the diagnosis of COVID-19. In this case report, we describe our experience in detection of COVID-19 from a confirmed patient using nucleic acid test of bronchoalveolar-lavage fluid MESHD ( BALF MESHD) samples but not nasopharyngeal swabs.Case presentationWe present a case of severely ill COVID-19 infected 46-year-old man with fever HP fever MESHD, coughing HP and chest tightness HP chest tightness MESHD. We performed viral detection using his BALF MESHD samples and imaging method (CT) for confirmation. The patient received combination of interferonalfa-1b and ribavirin, lopinavir and ritonavir for antiviral treatment at different stages. Other medication was also given to him in combination for anti- inflammation MESHD, intestinal microbial regulation, phlegm elimination, liver protection and pulmonary fibrosis MESHD prevention purposes. We provided oxygen supply to him using BIPAP ventilator and high-flow humidification oxygen therapy instrument to facilitate respiration. The patient was cured and discharged.ConclusionThis case report described an effective supportive medication scheme to treat COVID-19 infected MESHD patient and emphasized the necessity of detection of the viral genome using BALF MESHD samples and its significance in the diagnosis and prognosis of the disease.

    Clinical Pathology of Critical Patient with Novel Coronavirus Pneumonia HP (COVID-19)

    Authors: Weiren Luo; Hong Yu; Jizhou Gou; Xiaoxing Li; Yan Sun; Jinxiu Li; Lei Liu

    id:202002.0407/v4 Date: 2020-03-09 Source: Preprints.org

    Background Critical patients with novel coronavirus pneumonia MESHD pneumonia HP ( COVID-19) have worse outcome and high mortality. However, the histopathology of critical patient with COVID-19 remains undisclosed. Methods We performed the whole lung biopsy, and described the pathological changes of critical COVID-19 patient done with transplant by HE staining, immunohistochemistry and special staining observed under the microscopy. Findings The whole lungs displayed diffuse congestive appearance and partly haemorrhagic necrosis MESHD on gross examination. The haemorrhagic necrosis MESHD was prominently present in outer edge of the right lower lung. The cut surfaces of the lung displayed severe congestive and haemorrhagic changes. The main pathological changes showed massive pulmonary interstitial fibrosis MESHD, and partly hyaline degeneration MESHD, variable degrees of hemorrhagic pulmonary infarction MESHD. Small vessels hyperplasia MESHD, vessel wall thickening, lumen stenosis, occlusion and microthrombosis MESHD formation. Focal monocytes, lymphocytes and plasma SERO cells infiltrating into pulmonary HP interstitium. Bronchiolitis HP Bronchiolitis MESHD and alveolitis with proliferation, atrophy MESHD, desquamation MESHD and squamous MESHD metaplasia of epithelial cells. Atrophy MESHD, vacuolar degeneration, proliferation, desquamation MESHD and squamous MESHD metaplasia in alveolar epithelial MESHD cells. Alveolar MESHD cavity congestion was prominent, and contained mucus, edema HP edema MESHD fluid, desquamated epithelial cells, and inflammatory cells. We also found several multinucleate giant cells and intracytoplasmic viral inclusion bodies. Special stains including Masson stain, sirius red staining, reticular fibers staining indicated massive pulmonary interstitial fibrosis MESHD. Immunohistochemistry showed positive for immunity cells including CD3, CD4, CD8, CD20, CD79a, CD5, CD38 and CD68. Interpretation We demonstrate the pathological findings of critical patient with COVID-19, which might provide a deep insight of the pathogenesis and severity of this disease.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.